secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001933414-24-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Q1 net loss $31.5M; cash $338.6M; Advance-HTN topline due Q4 2024
---------------------------------------------------------------------------

- Net loss of $31.5M for Q1 2024, up from $12.6M in Q1 2023; R&D expenses $30.8M.
- Cash, equivalents and investments $338.6M as of March 31, 2024; private placement net ~$116M in Q1.
- Advance-HTN pivotal trial topline data expected in Q4 2024.
- Launch-HTN Phase 3 trial topline data anticipated in 2H 2025.
- Explore-CKD Phase 2 topline data expected Q4 2024 to Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/0001933414-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/mlys-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer